BACKGROUND: Myeloid-related protein (MRP)-8 (S100A8) and MRP-14 (S100A9) are members of the S100 family of calcium-modulated proteins that regulate myeloid cell function and control inflammation, in part, through activation of Toll-like receptor-4 and the receptor for advanced glycation end products. A transcriptional profiling approach in patients with acute coronary syndromes identified MRP-14 as a novel predictor of myocardial infarction. Further studies demonstrated that elevated plasma levels of MRP-8/14 heterodimer predict increased risk of first and recurrent cardiovascular events. Beyond its serving as a risk marker, whether MRP-8/14 participates directly in vascular inflammation and disease remains unclear. METHODS AND RESULTS: We evaluated vascular inflammation in wild-type and MRP-14-deficient (MRP-14(-/-)) mice that lack MRP-8/14 complexes with experimental arterial injury, vasculitis, or atherosclerosis. After femoral artery wire injury, MRP-14(-/-) mice had significant reductions in leukocyte accumulation, cellular proliferation, and neointimal formation compared with wild-type mice. In a cytokine-induced local Shwartzman-like reaction that produces thrombohemorrhagic vasculitis, MRP-14(-/-) mice had significant reductions in neutrophil accumulation, lesion severity, and hemorrhagic area. In response to high-fat feeding, mice doubly deficient in apolipoprotein E and MRP-8/14 complexes had attenuation in atherosclerotic lesion area and in macrophage accumulation in plaques compared with mice deficient in apolipoprotein E alone. CONCLUSIONS: This study demonstrates that MRP-8/14 broadly regulates vascular inflammation and contributes to the biological response to vascular injury by promoting leukocyte recruitment.
BACKGROUND:Myeloid-related protein (MRP)-8 (S100A8) and MRP-14 (S100A9) are members of the S100 family of calcium-modulated proteins that regulate myeloid cell function and control inflammation, in part, through activation of Toll-like receptor-4 and the receptor for advanced glycation end products. A transcriptional profiling approach in patients with acute coronary syndromes identified MRP-14 as a novel predictor of myocardial infarction. Further studies demonstrated that elevated plasma levels of MRP-8/14 heterodimer predict increased risk of first and recurrent cardiovascular events. Beyond its serving as a risk marker, whether MRP-8/14 participates directly in vascular inflammation and disease remains unclear. METHODS AND RESULTS: We evaluated vascular inflammation in wild-type and MRP-14-deficient (MRP-14(-/-)) mice that lack MRP-8/14 complexes with experimental arterial injury, vasculitis, or atherosclerosis. After femoral artery wire injury, MRP-14(-/-) mice had significant reductions in leukocyte accumulation, cellular proliferation, and neointimal formation compared with wild-type mice. In a cytokine-induced local Shwartzman-like reaction that produces thrombohemorrhagic vasculitis, MRP-14(-/-) mice had significant reductions in neutrophil accumulation, lesion severity, and hemorrhagic area. In response to high-fat feeding, mice doubly deficient in apolipoprotein E and MRP-8/14 complexes had attenuation in atherosclerotic lesion area and in macrophage accumulation in plaques compared with mice deficient in apolipoprotein E alone. CONCLUSIONS: This study demonstrates that MRP-8/14 broadly regulates vascular inflammation and contributes to the biological response to vascular injury by promoting leukocyte recruitment.
Authors: Marie-Pierre Manitz; Basil Horst; Stephan Seeliger; Anke Strey; Boris V Skryabin; Matthias Gunzer; Werner Frings; Frank Schönlau; Johannes Roth; Clemens Sorg; Wolfgang Nacken Journal: Mol Cell Biol Date: 2003-02 Impact factor: 4.272
Authors: Carle Ryckman; Shaun R McColl; Karen Vandal; Rinaldo de Médicis; André Lussier; Patrice E Poubelle; Philippe A Tessier Journal: Arthritis Rheum Date: 2003-08
Authors: Koichi Shimizu; Peter Libby; Viviane Z Rocha; Eduardo J Folco; Rica Shubiki; Nir Grabie; Sunyoung Jang; Andrew H Lichtman; Ayako Shimizu; Nancy Hogg; Daniel I Simon; Richard N Mitchell; Kevin Croce Journal: Circulation Date: 2011-12-05 Impact factor: 29.690
Authors: Jinkwan Kim; Rakesh Bhattacharjee; Abdelnaby Khalyfa; Leila Kheirandish-Gozal; Oscar Sans Capdevila; Yang Wang; David Gozal Journal: Am J Respir Crit Care Med Date: 2011-11-10 Impact factor: 21.405
Authors: Andrei Maiseyeu; Marcus A Badgeley; Thomas Kampfrath; Georgeta Mihai; Jeffrey A Deiuliis; Cuiqing Liu; Qinghua Sun; Sampath Parthasarathy; Daniel I Simon; Kevin Croce; Sanjay Rajagopalan Journal: Arterioscler Thromb Vasc Biol Date: 2012-02-02 Impact factor: 8.311
Authors: Cole Vonder Haar; Gail D Anderson; Brandy E Elmore; Lynn H Moore; Amanda M Wright; Eric D Kantor; Fred M Farin; Theo K Bammler; James W MacDonald; Michael R Hoane Journal: J Neurotrauma Date: 2014-01-20 Impact factor: 5.269
Authors: Ling Yan; Per Bjork; Radu Butuc; Joseph Gawdzik; Judy Earley; Gene Kim; Marion A Hofmann Bowman Journal: Atherosclerosis Date: 2013-02-28 Impact factor: 5.162
Authors: Ryo Kawakami; Shunsuke Katsuki; Richard Travers; Dayanna Carolina Romero; Dakota Becker-Greene; Livia Silva Araujo Passos; Hideyuki Higashi; Mark C Blaser; Galina K Sukhova; Josef Buttigieg; David Kopriva; Ann Marie Schmidt; Daniel G Anderson; Sasha A Singh; Luis Cardoso; Sheldon Weinbaum; Peter Libby; Masanori Aikawa; Kevin Croce; Elena Aikawa Journal: Arterioscler Thromb Vasc Biol Date: 2020-05-28 Impact factor: 8.311
Authors: Yunmei Wang; Jackelyn B Golden; Yi Fritz; Xiufen Zhang; Doina Diaconu; Maya I Camhi; Huiyun Gao; Sean M Dawes; Xianying Xing; Santhi K Ganesh; Johann E Gudjonsson; Daniel I Simon; Thomas S McCormick; Nicole L Ward Journal: JCI Insight Date: 2016-12-08